search
Back to results

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Primary Purpose

Craniopharyngioma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Proton Therapy
Surgery
Sponsored by
St. Jude Children's Research Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Craniopharyngioma focused on measuring Brain tumor, Pediatrics, Radiation therapy, Proton therapy, Surgery

Eligibility Criteria

undefined - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Craniopharyngioma diagnosed by histology, cytology or neuroimaging or intra-operative assessment
  • Patients ages 0-21 years at the time of diagnosis

Exclusion Criteria:

  • Prior history of fractionated radiation therapy
  • Prior treatment with intracystic P-32 or intracystic bleomycin
  • Pregnant females are excluded. Radiation has teratogenic or abortifacient effects

Sites / Locations

  • St. Jude Children's Research HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Tumor-Surgery

Tumor-No Surgery

Arm Description

Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups. If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups.

Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.

Outcomes

Primary Outcome Measures

Progression-free survival (PFS)
PFS is defined as the interval of time from the initiation of radiation therapy (RT) until the earliest of the events: death from any cause; and disease progression.
Overall survival (OS)
OS is defined as the interval of time from the initiation of RT until the death from any cause.

Secondary Outcome Measures

Compare incidence of first cystic intervention with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
The cumulative incidence estimates of first cystic intervention for cystic fluctuations after proton therapy. Competing events are death, disease progression and development of a new or secondary tumor.
Compare event-free survival (EFS) with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
Kaplan-Meier estimates will be provided of EFS, which is measured from initiation of proton therapy until the earliest of PFS failure or secondary malignancy or new tumor, or surgical intervention for cystic fluctuation. Patients who have not experienced an event will be censored at their last date of contact.
Compare survival distributions with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
Final analyses will also compare survival distributions using the log-rank test for patients treated with limited surgery and proton therapy on this protocol with the updated SJCRH cohort of patients treated with limited surgery and photon irradiation. The definition of survival will be defined in same way for both cohorts. This secondary analysis will be stratified by whether or not patients have a cerebrospinal fluid (CSF) shunt in place prior to irradiation and race (black versus white).
Compare survival distributions between groups
To estimate the survival distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with limited surgery and proton therapy. A stratified log-rank test will be used to compare the distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and the distributions observed for patients treated with limited surgery and proton therapy.

Full Information

First Posted
June 1, 2016
Last Updated
August 22, 2023
Sponsor
St. Jude Children's Research Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02792582
Brief Title
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Official Title
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 22, 2016 (Actual)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Jude Children's Research Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Craniopharyngioma is a rare brain tumor that affects both children and adults. It arises in a region of the brain near the pituitary gland, visual pathways, and central blood vessels. Patients often present with headache, loss of vision or delayed growth. In some instances they may present with imbalance of water and salts in the body. The treatment for craniopharyngioma may be radical surgery or a combination of surgery and radiation therapy. In some instances surgery is not required. If the tumor cannot be completely removed, radiation therapy may be required. In this study we will use the most advanced form of proton therapy which is called intensity-modulated proton therapy. This is a newer form of radiation therapy which has a number of advantages over older forms of proton therapy and conventional radiation therapy using x-rays. The main goal of this study is to learn if proton therapy will effectively treat patients with craniopharyngioma brain tumors and reduce side effects compared to more traditional forms of radiation therapy.
Detailed Description
This study will include participants who are diagnosed or presumed to have craniopharyngioma based on neuroimaging, intra-operative assessment, or the evaluation of cyst fluid or tissue after limited or radical surgery. When possible, participants will be enrolled on protocol prior to surgery. PRIMARY OBJECTIVE: To estimate the distributions of progression-free and overall survival for children and young adults with craniopharyngioma treated with intensity-modulated proton therapy while monitoring for excessive central nervous system necrosis, clinically significant vasculopathy, and permanent neurological conditions or deficits. SECONDARY OBJECTIVES: To estimate the cumulative incidence of cystic intervention and the event-free survival distribution for children and young adults with craniopharyngioma treated with intensity-modulated proton therapy; and to compare the distributions of progression-free, event-free and overall survival with the distributions for the St. Jude Children's Research Hospital (SJCRH) cohort of patients treated with photon therapy on which the design of this trial is based. To estimate the cumulative incidence of cystic intervention and the distributions of progression-free survival, overall survival and the event-free survival for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with proton therapy. OTHER PRE-SPECIFIED OBJECTIVES: To explore potential associations of clinical and treatment factors with the incidence and severity of neurological, endocrine and cognitive deficits in children and young adults with craniopharyngioma treated with radical surgery or proton therapy. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated with photon therapy. Using specific measures of sleep quality, excessive daytime sleepiness, daytime activity, circadian rhythm, fatigue, symptom distresses, and quality of life, explore associations of sleep, fatigue and quality of life with other measures of central nervous system (CNS) effects, clinical and treatment factors in children and young adults with craniopharyngioma treated with radical surgery or proton therapy. To evaluate and explore differences in physical performance and movement in children and young adults with craniopharyngioma treated with radical surgery or proton therapy, using specific measures of overall physical performance, flexibility, balance, coordination, muscle strength and power, and cardiopulmonary fitness. Estimate and compare the response of residual tumor and the incidence and severity of structural, functional and vascular effects of normal brain in children and young adults with craniopharyngioma after treatment with radical surgery or proton therapy using specific methods of diffusion, contrast-enhancement, vascular and functional neuroimaging, and explore the association between these and other measures of CNS effects and clinical and treatment factors. Investigate the feasibility of using positron emission tomography (PET) as an in vivo dose and distal edge verification system for craniopharyngioma patients treated with proton therapy. Measure growth factor and cytokine responses in children and young adults with craniopharyngioma after treatment with radical surgery or proton therapy, and explore associations between these and other measures of CNS effects and clinical and treatment factors. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated with photon therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Craniopharyngioma
Keywords
Brain tumor, Pediatrics, Radiation therapy, Proton therapy, Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tumor-Surgery
Arm Type
Active Comparator
Arm Description
Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups. If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups.
Arm Title
Tumor-No Surgery
Arm Type
Active Comparator
Arm Description
Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
Intervention Type
Radiation
Intervention Name(s)
Proton Therapy
Other Intervention Name(s)
Radiation therapy
Intervention Description
The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
Intervention Type
Procedure
Intervention Name(s)
Surgery
Other Intervention Name(s)
Tumor resection
Intervention Description
When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
Primary Outcome Measure Information:
Title
Progression-free survival (PFS)
Description
PFS is defined as the interval of time from the initiation of radiation therapy (RT) until the earliest of the events: death from any cause; and disease progression.
Time Frame
3 years after initiation of proton therapy
Title
Overall survival (OS)
Description
OS is defined as the interval of time from the initiation of RT until the death from any cause.
Time Frame
3 years after initiation of proton therapy
Secondary Outcome Measure Information:
Title
Compare incidence of first cystic intervention with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
Description
The cumulative incidence estimates of first cystic intervention for cystic fluctuations after proton therapy. Competing events are death, disease progression and development of a new or secondary tumor.
Time Frame
3 years after initiation of proton therapy
Title
Compare event-free survival (EFS) with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
Description
Kaplan-Meier estimates will be provided of EFS, which is measured from initiation of proton therapy until the earliest of PFS failure or secondary malignancy or new tumor, or surgical intervention for cystic fluctuation. Patients who have not experienced an event will be censored at their last date of contact.
Time Frame
3 years after initiation of proton therapy
Title
Compare survival distributions with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
Description
Final analyses will also compare survival distributions using the log-rank test for patients treated with limited surgery and proton therapy on this protocol with the updated SJCRH cohort of patients treated with limited surgery and photon irradiation. The definition of survival will be defined in same way for both cohorts. This secondary analysis will be stratified by whether or not patients have a cerebrospinal fluid (CSF) shunt in place prior to irradiation and race (black versus white).
Time Frame
3 years after initiation of proton therapy
Title
Compare survival distributions between groups
Description
To estimate the survival distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with limited surgery and proton therapy. A stratified log-rank test will be used to compare the distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and the distributions observed for patients treated with limited surgery and proton therapy.
Time Frame
3 years after initiation of proton therapy
Other Pre-specified Outcome Measures:
Title
Change in vision status compared between groups
Description
Vision status will be classified into three groups (None, Impaired, Severe). Information recorded in the clinical neurology form will also be used, as will the ophthalmology data sheet and NCI CTCAE v4.0 when relevant. The distribution of outcomes is ordinal categorical and percentages will be estimated. Mixed-effects Proportional Odds Regression will be used to estimate the change of vision over time, and compare severity of vision in the two treatment groups adjusted by confound factors.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Change in hearing status compared between groups
Description
Hearing will be categorized as normal if all thresholds are within 0-20 decibels hearing level (dB HL) and otherwise abnormal. Generalized Estimating Equations (GEE) with logistic link will be used to explore the trend over time and investigate impacts of specific clinical and treatment factors on hearing loss. In the presence of missing data, Weighted GEE will be employed to address missingness. In addition, the cumulative incidence of hearing loss will be estimated with death as a competing risk.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare number of neurological deficits to participants treated using conventional radiation therapy at St. Jude Children's Research Hospital
Description
The incidence and severity of neurological deficits in children and young adults with craniopharyngioma treated with radical surgery or limited surgery and proton therapy. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated using photons.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare number of endocrine deficits to participants treated using conventional radiation therapy at St. Jude Children's Research Hospital
Description
The incidence and severity of endocrine deficits in children and young adults with craniopharyngioma treated with radical surgery or limited surgery and proton therapy. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated using photons.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare number of cognitive deficits to participants treated using conventional radiation therapy at St. Jude Children's Research Hospital
Description
The incidence and severity of cognitive deficits in children and young adults with craniopharyngioma treated with radical surgery or limited surgery and proton therapy. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated using photons.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare quality of life between groups
Description
Analysis will be stratified by treatment arms (radical surgery vs. limited surgery and proton therapy), descriptive statistics of the longitudinal assessments of quality of life will be described. Specifically, on a yearly basis starting from the pre-treatment time point to year 5 post treatment initiation, quality of life in patients ≥ 2 years of age as measured by the Peds QoL v4 and the Peds QoL brain tumor module will be reported. On a more frequent basis (every 3 months in the first year after treatment initiation and every 6 months afterwards), sleep complaints in patients ≥ 8 years of age as measured Epworth Sleepiness Scale will be reported and fatigue in patients ≥ 2 years of age as measured by The Peds QL Multidimensional Fatigue scale will be reported. Sleep disorders at diagnosis and 3 years after the initiation of treatment will be measured by overnight polysomnography.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare physical performance and movement between groups
Description
Physical performance measures will be obtained at baseline, 6, 12, 24, 36, 48 and 60 months. For the surgery only group, baseline is measured immediately after surgery. For the limited surgery and proton therapy group, the baseline is measured immediately before proton therapy. The baselines in the two groups are measured approximately at the same time so the comparisons between the two groups are reasonable. Descriptive statistics of the outcomes for each group will be provided.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Incidence of vasculopathy between groups
Description
Cumulative incidence of vasculopathy with at least major symptoms (i.e., Vasculopathy grade > 2) will be estimated for the first occurrence of vasculopathy, where death, disease progression, and development of a new or secondary tumor will be considered as completing events. Vasculopathy will be graded 3-5 according to NCI CTCAE v4.0.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Compare incidence of central nervous effects between groups
Description
Quantitative measures of structural and functional changes in the brain over time will be described using mixed effects models. Associations of functional and structural changes in the brain with cognitive variables will be investigated using mixed effects models which will include demographic, imaging and clinical factors, such as age at diagnoses, gender, race and socioeconomic status, fractional anisotropy (FA), apparent diffusion coefficient (ADC), hydrocephalus and presence of CSF shunt, and pre-proton therapy growth hormone deficiency.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Percentage of participants who were successfully evaluated with an in vivo dose and distal edge verification system
Description
The percentage of patients with PET scans where loss of signal intensity or resolution was observed will be estimated with 95% exact confidence intervals.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Change in growth factor response
Description
The planned analyses based on this data will mainly utilize longitudinal models.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Change in cytokine response
Description
The planned analyses based on this data will mainly utilize longitudinal models.
Time Frame
From baseline to 5 years following start of proton therapy
Title
Number and type of germline variations associated with craniopharyngioma
Description
Descriptive statistics will be provided for known candidate genes and gene mutations. Analysis will be performed using current processes available at the time of analysis.
Time Frame
5 years following start of proton therapy

10. Eligibility

Sex
All
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Craniopharyngioma diagnosed by histology, cytology or neuroimaging or intra-operative assessment Patients ages 0-21 years at the time of diagnosis Exclusion Criteria: Prior history of fractionated radiation therapy Prior treatment with intracystic P-32 or intracystic bleomycin Pregnant females are excluded. Radiation has teratogenic or abortifacient effects
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas E. Merchant, DO, PhD
Phone
866-278-5833
Email
referralinfo@stjude.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas E. Merchant, DO, PhD
Organizational Affiliation
St. Jude Children's Research Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Jude Children's Research Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas E Merchant, DO, PhD
Phone
866-278-5833
Email
referralinfo@stjude.org
First Name & Middle Initial & Last Name & Degree
Thomas E Merchant, DO, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
33607632
Citation
Wilson LJ, Pirlepesov F, Moskvin V, Li Z, Guo Y, Li Y, Merchant TE, Faught AM. Proton therapy delivery method affects dose-averaged linear energy transfer in patients. Phys Med Biol. 2021 Apr 1;66(7). doi: 10.1088/1361-6560/abe835. Erratum In: Phys Med Biol. 2021 Jul 05;66(14):
Results Reference
derived
Links:
URL
http://www.stjude.org
Description
St. Jude Children's Research Hospital
URL
http://www.stjude.org/protocols
Description
Clinical Trials Open at St. Jude

Learn more about this trial

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

We'll reach out to this number within 24 hrs